| All NSAIDs | All studies | 14 | 443 641 | 1.17 (0.99 to 1.37) | 1.32 (1.29 to 1.35) |
| Large studies (>10 000 controls) | 11 | 426 232 | 1.34 (1.18 to 1.51) | 1.40 (1.37 to 1.43) |
| Small studies (<10 000 controls) | 3 | 17 409 | 0.70 (0.39 to 1.27) | 0.61 (0.56 to 0.67) |
| European | 8 | 326 471 | 1.41 (1.25 to 1.59) | 1.50 (1.46 to 1.55) |
| North American | 6 | 117 170 | 0.91 (0.66 to 1.24) | 1.02 (0.98 to 1.06) |
| Matched controls | 6 | 231 922 | 1.40 (1.17 to 1.68) | 1.38 (1.33 to 1.42) |
| Unmatched controls | 8 | 211 719 | 1.01 (0.73 to 1.36) | 1.26 (1.22 to 1.30) |
| Industrial support | 6 | 64 512 | 0.98 (0.66 to 1.43) | 1.05 (1.00 to 1.10) |
| No industrial support | 8 | 379 129 | 1.33 (1.14 to 1.55) | 1.41 (1.37 to 1.45) |
| Specific NSAIDs | Naproxen | 11 | 384 324 | 1.03 (0.83 to 1.29) | 1.06 (1.00 to 1.13) |
| Ibuprofen | 8 | 286 089 | 1.08 (0.80 to 1.46) | 1.14 (1.09 to 1.19) |
| Diclofenac | 7 | 260 791 | 1.12 (0.68 to 1.87) | 1.07 (1.01 to 1.12) |
| Celecoxib | 7 | 319 841 | 1.01 (0.73 to 1.39) | 1.02 (0.94 to 1.10) |
| Rofecoxib | 7 | 203 487 | 1.19 (0.70 to 2.01) | 1.14 (1.05 to 1.24) |